Results 61 to 70 of about 121,016 (287)

Application progress on immunotherapy with chimeric antigen receptor T cell in patients with hematological malignancies

Huli yanjiu, 2020
Reviewing application progress on immunotherapy with chimeric antigen receptor T cell（CAR⁃T） in patients with hematological malignancies from 4 aspects,such as collection,pretreatment,note on cell reinfusion,and treatment complication of chimeric antigen
MENG Rui, XU Li, WAN Ying
doaj  

Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma

Nature Communications, 2020
Chimeric antigen receptor (CAR)-based therapy for the treatment of liver cancer represents a promising therapeutic strategy. Here the authors show that CD147-targeting CAR-NK or CAR-T can induce anti-tumor activity against hepatocellular carcinoma in ...
Hsiang-chi Tseng, Wei Xiong, Saiaditya Badeti, Yan Yang, Minh Ma, Ting Liu, Carlos A. Ramos, Gianpietro Dotti, Luke Fritzky, Jie-gen Jiang, Qing Yi, James Guarrera, Wei-Xing Zong, Chen Liu, Dongfang Liu   +14 more
doaj   +1 more source

Design of diversified chimeric antigen receptors through rational module recombination

iScience, 2023
Summary: Chimeric antigen receptor (CAR)-T cells have shown great promise in cancer therapy. However, the anti-tumor efficiency is limited due to the CAR-induced T cell apoptosis or exhaustion.
Wen Si, Ying-Ying Fan, Shi-Zhen Qiu, Xin Li, Er-Yi Wu, Jian-Qi Ju, Wen Huang, Hao-Peng Wang, Ping Wei   +8 more
doaj   +1 more source

Development of novel adenoviral vectors to overcome challenges observed with HAdV-5 based constructs [PDF]

, 2011
Recombinant vectors based on human adenovirus serotype 5 (HAdV-5) have been extensively studied in pre-clinical models and clinical trials over the last two decades.
Julio Alonso-Padilla, Tibor Papp, Győző L Kaján, Mária Benkő, Menzo Havenga, Angelique Lemckert, Balázs Harrach, Andrew H Baker, Harrach, Benkő, Liu, Reddy, Benevento, Reddy, Rux, Bergelson, Wickham, Wolfrum, Arnberg, Burckhardt, Vectors used in gene therapy clinical trials., Appaiahgari, Pearson, Wilson, Chorny, Van Kampen, George, Ranki, Hendrickx, Ilan, Schaack, Aldhamen, Machitani, Appledorn, Perreau, Minamitani, Khare, Lyons, Carlisle, Seiradake, Xu, Khare, Qiu, Waddington, Kalyuzhniy, Vigant, Alba, Jonsson, Lenman, Doronin, Xu, Eichholz, Ganesan, Alemany, Piccolo, Mocanu, Piccolo, Khare, Xu, Lasaro, Zak, Zhang, Barouch, Bradley, Roberts, Gall, Fausther-Bovendo, Sumida, Miyazawa, Teigler, Smith, Molinier-Frenkel, Heemskerk, Hutnick, Tang, Olive, Leen, Joshi, Osada, Perreau, Seregin, Seregin, Fontanellas, Cerullo, Brunetti-Pierri, Seregin, Farrow, McConnell, Belousova, Seregin, Capasso, Green, Doronin, Kreppel, Matsui, Suzuki-Kouyama, Prill, Krasnykh, Zabner, Havenga, Lecollinet, Coughlan, Granio, Parker, Guse, Smith, Nicol, Bruder, Bruder, Baden, Coughlan, Mück-Häusl, Bi, Abbink, Abbink, Mastrangeli, Abrahamsen, Brough, Stone, Sirena, Stone, Seshidhar Reddy, Hemminki, Creech, Vogels, Kuhn, Di, Havenga, Kahl, Vogels, Lemckert, Teigler, Tameris, Ouédraogo, Keefer, Baden, Gilbert, Baden, Zahn, Johnson, Dakin, Alexander, Alexander, Gurwith, Lemiale, Jarecki-Khan, Saderi, Ko, Bangari, Ayalew, Hammond, Tuboly, Fischer, Hu, Greenall, Brake, Lopez-Gordo, Kremer, Soudais, Soudais, Silva, Puig, Fernandes, Tandon, Bangari, Nguyen, Lenaerts, Ying, van Olphen, Zakhartchouk, Cauthen, Reddy, Reddy, Li, Lenaerts, Sharma, Sharma, Roy, Cohen, Xiang, Quinn, Farina, Roy, Colloca, Barnes, O'Hara, Antrobus, Stanley, Tan, Michou, Ojkic, Sheppard, Corredor, Cherenova, Shashkova, Logunov, Both, Xu, Khatri, Hofmann, Löser, Both, Martiniello-Wilks, Tang, Fraser, Bridgeman, Doszpoly, Cortés-Hinojosa, Wigand, Kajon, Guy, Benkö, Lu, Günes, Wellehan, Phan   +215 more
core   +4 more sources

Engineering better chimeric antigen receptor T cells [PDF]

Experimental Hematology & Oncology, 2020
AbstractCD19-targeted CAR T cells therapy has shown remarkable efficacy in treatment of B cell malignancies. However, relapse of primary disease remains a major obstacle after CAR T cells therapy, and the majority of relapses present a tumor phenotype with retention of target antigen (antigen-positive relapse), which highly correlate with poor CAR T ...
Hao Zhang, Pu Zhao, He Huang
openaire   +3 more sources

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

Molecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian, Sriraam Sivachandran, Melissa Galati, Brandon Ramchatesingh, Hibo Rijal, Johnny Hanna, Elena Netchiporouk, May Chergui, Margaret Redpath, Samy Abou Setah, Ivan V. Litvinov   +10 more
wiley   +1 more source

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source

Genetic engineering of chimeric antigen receptors using lamprey derived variable lymphocyte receptors

Molecular Therapy: Oncolytics, 2016
Chimeric antigen receptors (CARs) are used to redirect effector cell specificity to selected cell surface antigens. Using CARs, antitumor activity can be initiated in patients with no prior tumor specific immunity.
Robert Moot, Sunil S Raikar, Lauren Fleischer, Melissa Querrey, Daniel E Tylawsky, Hirotomo Nakahara, Christopher B Doering, H Trent Spencer   +7 more
doaj   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

Transcriptional reprogramming via signaling domains of CD2, CD28, and 4-1BB

iScience
Summary: Costimulatory signals provided to T cells during antigen encounter have a decisive role in the outcome of immune responses. Here, we used chimeric receptors harboring the extracellular domain of mouse inducible T cell costimulator (mICOS) to ...
Annika De Sousa Linhares, Sumana Sharma, Peter Steinberger, Judith Leitner   +3 more
doaj   +1 more source